Scheme approved by National Company Law Tribunal (NCLT), Ahmedabad Bench on July 6, 2026
Effective date: July 8, 2026 with appointed date of January 21, 2026
Share exchange ratio: 51 equity shares of Torrent (face value ₹5) for every 100 equity shares of JB Pharma (face value ₹1)
Company allotted 4,19,22,416 fully paid-up equity shares on July 20, 2026 to eligible shareholders of JB Pharma
JB Pharma financials included from appointed date: Total assets of ₹4,823.50 crores, revenue of ₹712.74 crores, net profit of ₹133.97 crores for period from January 21, 2026 to March 31, 2026
Exceptional Items
Q2 FY27: ₹10 crores litigation settlement
H1 FY27: ₹31 crores total exceptional items
Includes regulatory and statutory fees related to JB Pharma acquisition and merger
Includes ₹19 crores inventory write-off due to fire incident at erstwhile JB Pharma warehouse (insurance claim under assessment)
Includes severance compensation of ₹19 crores for restructuring of JB Pharma's distribution network (for year ended March 31, 2026)
Debt and Security
Listed non-convertible debentures: ₹10,990 crores as at September 30, 2026
Secured by first ranking exclusive charge by way of hypothecation over designated account assets and specified trademarks
Security cover exceeds 110% of principal amount and interest accrued
Board Meeting Details
Meeting held on October 23, 2026
Commenced at 2:00 PM and concluded at 4:00 PM
Results reviewed by Audit Committee and approved by Board of Directors
